Now out of business ith the principals moved to another firms,, Imetrx dhad been organized around development of intravascular catheter-based systems to detect and treat life threatening vulnerable atherosclerotic plaque. The Company had an exclusive worldwide license from Stanford University for technologies conceived by Dr. H. William Strauss, Chief of Nuclear Medicine. In addition, the Company expanded its core technologies through internal development and exclusive in-licensing of complementary technologies
